These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 28748348)

  • 1. Impact of Genetic Polymorphisms on Phenytoin Pharmacokinetics and Clinical Outcomes in the Middle East and North Africa Region.
    Dagenais R; Wilby KJ; Elewa H; Ensom MHH
    Drugs R D; 2017 Sep; 17(3):341-361. PubMed ID: 28748348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequencies of CYP2C9 polymorphisms in North Indian population and their association with drug levels in children on phenytoin monotherapy.
    Chaudhary N; Kabra M; Gulati S; Gupta YK; Pandey RM; Bhatia BD
    BMC Pediatr; 2016 May; 16():66. PubMed ID: 27179628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A meta-analysis of effects of
    Kanjanasilp J; Sawangjit R; Phanthaisong S; Borihanthanawuth W
    Pharmacogenomics; 2021 Jul; 22(10):629-640. PubMed ID: 34060344
    [No Abstract]   [Full Text] [Related]  

  • 4. CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects.
    Franco V; Perucca E
    Expert Opin Drug Metab Toxicol; 2015; 11(8):1269-79. PubMed ID: 26037375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms.
    Hung CC; Lin CJ; Chen CC; Chang CJ; Liou HH
    Ther Drug Monit; 2004 Oct; 26(5):534-40. PubMed ID: 15385837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association between CYP2C9/2C19 polymorphisms and phenytoin maintenance doses in Asian epileptic patients: A systematic review and meta-analysis
.
    Liao K; Liu Y; Ai CZ; Yu X; Li W
    Int J Clin Pharmacol Ther; 2018 Jul; 56(7):337-346. PubMed ID: 29628024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contributions of CYP2C9/CYP2C19 genotypes and drug interaction to the phenytoin treatment in the Korean epileptic patients in the clinical setting.
    Lee SY; Lee ST; Kim JW
    J Biochem Mol Biol; 2007 May; 40(3):448-52. PubMed ID: 17562299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Development of rapid genotyping methods for single nucleotide polymorphisms of cytochrome P450 2C9 (CYP2C9) and cytochrome P450 2C19 (CYP2C19) and their clinical application in pediatric patients with epilepsy].
    Yamamoto Y; Takahashi Y; Nishimura S; Ikumi Y; Mishima N; Kagawa Y
    Yakugaku Zasshi; 2011; 131(5):809-15. PubMed ID: 21532277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetic Variants and Plasma Concentrations of Antiseizure Drugs: A Systematic Review and Meta-Analysis.
    Milosavljevic F; Manojlovic M; Matkovic L; Molden E; Ingelman-Sundberg M; Leucht S; Jukic MM
    JAMA Netw Open; 2024 Aug; 7(8):e2425593. PubMed ID: 39115847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of polymorphic metabolism enzymes on serum phenytoin level.
    Ozkaynakci A; Gulcebi MI; Ergeç D; Ulucan K; Uzan M; Ozkara C; Guney I; Onat FY
    Neurol Sci; 2015 Mar; 36(3):397-401. PubMed ID: 25311916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical relevance of genetic polymorphism in CYP2C9 gene to pharmacodynamics and pharmacokinetics of phenytoin in epileptic patients: validatory pharmacogenomic approach to pharmacovigilance.
    Kousar S; Wafai ZA; Wani MA; Jan TR; Andrabi KI
    Int J Clin Pharmacol Ther; 2015 Jul; 53(7):504-16. PubMed ID: 25943175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics.
    Mamiya K; Ieiri I; Shimamoto J; Yukawa E; Imai J; Ninomiya H; Yamada H; Otsubo K; Higuchi S; Tashiro N
    Epilepsia; 1998 Dec; 39(12):1317-23. PubMed ID: 9860067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of polymorphisms of CYP2C9, CYP2C19, and ABCB1, and activity of P-glycoprotein with response to anti-epileptic drugs.
    Taur SR; Kulkarni NB; Gandhe PP; Thelma BK; Ravat SH; Gogtay NJ; Thatte UM
    J Postgrad Med; 2014; 60(3):265-9. PubMed ID: 25121365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy.
    Ortega-Vázquez A; Dorado P; Fricke-Galindo I; Jung-Cook H; Monroy-Jaramillo N; Martínez-Juárez IE; Familiar-López I; Peñas-Lledó E; LLerena A; López-López M
    Pharmacogenomics J; 2016 Jun; 16(3):286-92. PubMed ID: 26122019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy.
    Odani A; Hashimoto Y; Otsuki Y; Uwai Y; Hattori H; Furusho K; Inui K
    Clin Pharmacol Ther; 1997 Sep; 62(3):287-92. PubMed ID: 9333104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of CYP2C polymorphisms on the pharmacokinetics of phenytoin in Japanese patients with epilepsy.
    Hashimoto Y; Otsuki Y; Odani A; Takano M; Hattori H; Furusho K; Iui K
    Biol Pharm Bull; 1996 Aug; 19(8):1103-5. PubMed ID: 8874828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Association between genetic polymorphisms of CYP2C19 and CYP2C9 and phenytoin serum concentration].
    Huang Y; Yang JF; Qi XL; Wang YQ; Wang WZ; Chen B
    Zhonghua Yi Xue Za Zhi; 2004 Oct; 84(20):1686-9. PubMed ID: 15569425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Individualized phenytoin therapy for Japanese pediatric patients with epilepsy based on CYP2C9 and CYP2C19 genotypes.
    Yamamoto Y; Takahashi Y; Imai K; Miyakawa K; Ikeda H; Ueda Y; Yamaguchi T; Nasu H; Ohtani H; Shigematsu H; Kagawa Y; Inoue Y
    Ther Drug Monit; 2015 Apr; 37(2):229-35. PubMed ID: 25162219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP2C9*1B promoter polymorphisms, in linkage with CYP2C19*2, affect phenytoin autoinduction of clearance and maintenance dose.
    Chaudhry AS; Urban TJ; Lamba JK; Birnbaum AK; Remmel RP; Subramanian M; Strom S; You JH; Kasperaviciute D; Catarino CB; Radtke RA; Sisodiya SM; Goldstein DB; Schuetz EG
    J Pharmacol Exp Ther; 2010 Feb; 332(2):599-611. PubMed ID: 19855097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels.
    Kerb R; Aynacioglu AS; Brockmöller J; Schlagenhaufer R; Bauer S; Szekeres T; Hamwi A; Fritzer-Szekeres M; Baumgartner C; Ongen HZ; Güzelbey P; Roots I; Brinkmann U
    Pharmacogenomics J; 2001; 1(3):204-10. PubMed ID: 11908757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.